Tyrogenex Presents Phase 1 Study of X-82 for Wet AMD at the International Symposium on Ocular Pharmacology and Therapeutics Clinical
NEEDHAM, Mass. & PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Tyrogenex, a privately held company focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, announced data from its phase 1 safety study of X-82 at ISOPT.
